FDA Backs Drug for Diabetic Macular Edema
Ranibizumab (Lucentis), an eye injection, has gained Food and Drug Administration approval for treating diabetic macular edema (DME). This eye condition is associated with retinopathy and is caused by fluid leaking into and altering the macula, the part of the eye that produces sharp images. Macular edema can lead to blurred vision, vision loss, and, in severe cases, blindness. Ranibizumab works by blocking a protein that spurs the abnormal growth of leaky blood vessels in the eye. The medication is already approved to treat several other eye disorders. The FDA called the approval "a major development for the treatment of people whose vision is impaired by DME as a complication of their disease."